Target intelligence / Profile preview

UDP-N-acetylglucosamine transporter (SLC35A3)

Target
SLC35A3
Molecular classification
Transporter, Nucleotide sugar transporter, Membrane protein
01

Overview

UDP-N-acetylglucosamine transporter (SLC35A3) is a membrane-bound transporter protein of the solute carrier (SLC) family located in the Golgi apparatus. It functions primarily to move UDP-N-acetylglucosamine (UDP-GlcNAc) from the cytosol into the Golgi lumen, operating as an antiporter and exchanging UDP-GlcNAc for UMP[2][4]. This action supplies glycosyltransferases in the Golgi with the substrate required for the biosynthesis of branched N-glycans and keratan sulfate[2][4]. SLC35A3 is crucial for normal cell growth, development, and protein glycosylation. Mutations are linked to congenital glycosylation disorders, intellectual disability, epileptic encephalopathy, and skeletal abnormalities in humans and cattle[2][3]. In cancer, altered expression of SLC35A3 impacts cell proliferation, invasion, apoptosis, and immune cell infiltration, making it a potential biomarker and therapeutic target[1]. The transporter may also form functional complexes with other SLC35 proteins, integrating signals relevant for Golgi function and cellular metabolism[3].

Other names
Solute carrier family 35 member A3Golgi UDP-GlcNAc transporterAMRSS35A3UDP-N-acetylglucosamine transporterSolute carrier family 35 (UDP-N-acetylglucosamine (UDP-GlcNAc) transporter), member A3SLC35A3
02

Mechanism of action

Not established for drugs, but modulation would theoretically alter UDP-GlcNAc flux into the Golgi, affecting glycosylation, cell proliferation, and apoptosis

03

Biological functions

Transmembrane transport of UDP-N-acetylglucosamine into the Golgi lumenSupply of UDP-GlcNAc for protein glycosylation (particularly N-glycosylation and keratan sulfate biosynthesis)Antiport mechanism exchanging UDP-GlcNAc for UMPMay participate in cell communication and cellular metabolism, including DNA repair and energy metabolism pathwaysAssociated with immune cell infiltration and immune checkpoint expression in cancer
04

Disease associations

Congenital disorders of glycosylation (CDG)Epileptic encephalopathyArthrogryposis and skeletal abnormalitiesColorectal cancer (decreased SLC35A3 expression linked to poor prognosis)Triple-negative breast cancer (high SLC35A3 expression)Impaired intellectual development and neurological disease
05

Safety considerations

Potential for adverse effects on glycosylationCancer/immune-related concerns
06

Interacting drugs

None established
07

Biomarkers

SLC35A3 expression (low) as a prognostic biomarker in colorectal cancerPotential use in predicting immune cell infiltration and patient outcome in cancer

Beyond the preview

Go deeper on UDP-N-acetylglucosamine transporter (SLC35A3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on UDP-N-acetylglucosamine transporter (SLC35A3).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call